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Introduction: Several cases of sarcoidosis following treatment with interferon-α have been reported in the literature,
but those following interferon-β are very rare. We report the case of a patient with multiple sclerosis who developed
pulmonary and cutaneous sarcoidosis following treatment with Betaseron® (interferon-β-1b).
Case presentation: A 33-year-old Caucasian woman with a history of multiple sclerosis, treated with interferon-β-1b
for 2.5 years developed erythema nodosum in her lower limbs, a breast abscess, and unilateral adenopathy of her left
lung. A skin biopsy confirmed sarcoidosis. After the discontinuation of interferon-β-1b and treatment with
indomethacin and prednisolone, she recovered.
Conclusions: Sarcoidosis is considered one of the most common multiple sclerosis imitators with involvement of the
central nervous system. However, although rare, sarcoidosis can develop following treatment with interferon-β-1b and
should be considered in patients with multiple sclerosis treated with beta-interferons who develop pulmonary or
extra-pulmonary manifestations of sarcoidosis. Interferon-β-1b discontinuation is the first and most important step in
the treatment of such cases followed by treatment with corticosteroids.
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Sarcoidosis is a chronic inflammatory disease commonly
involving granulomatous involvement of different organs
[1]. The prevalence of the disease is three to five per
100,000, and the most common age of occurrence is be-
tween 25 and 40 years [2]. From an immunopathologic
point of view, interferon-γ (IFN-γ) plays an important role
in granuloma formation of this disease [3]. Evidence for
the role of other IFNs, such as IFN-α and β in the patho-
genesis is rarely reported. However, there are increasing re-
ports of sarcoidosis following treatment with IFN-α and
IFN-β in different diseases, including hepatitis C, renal cell
carcinoma, multiple myeloma, and multiple sclerosis (MS)
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Betaseron® (IFN-β-1b) treatment.Case presentation
A 33-year-old Caucasian woman developed paresthesia in
her lower limbs followed by ataxia in 2009. Magnetic res-
onance imaging of her central nervous system revealed the
presence of multiple hyperintense lesions in T2-weighted
images of her brain and spinal cord consistent with a diag-
nosis of MS. Some of the lesions on T1-weighted views
showed enhancement following intravenous infusion of
gadolinium. A survey for vasculitis, including anti-nuclear
antibody (ANA) and anti-phospholipid antibody, was nega-
tive and treatment with IFN-β-1b was initiated in the pa-
tient. At 2.5 years later and while on IFN-β-1b she
developed painful erythematous lesions on the anterior
sides of both her legs consistent with erythema nodosum.
A week later she developed pain, swelling, and erythema of
her left breast, dry cough, chills, and fever. Upon breastl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A section of breast biopsy. (a) Low power view of the
breast lesion showing excess mononuclear infiltration around fat
space with a multinucleated giant cell in periphery. Hematoxylin and
eosin (×100). (b) High power view of a well-formed granuloma
composed of aggregation of epithelioid histiocytes with
multinucleated giant cells. Hematoxylin and eosin (×200).
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mensions of 7×7cm was discovered. Her pulmonary exam-
ination was normal, and her abdomen did not have
organomegaly. Multiple erythema nodosum lesions with
dimensions of 4×5cm were observed in both her legs. She
had no previous history of trauma to her breast tissue. La-
boratory findings revealed hemoglobin of 9.5 and an
erythrocyte sedimentation rate of 123. The results of vas-
culitis tests, including ANA, anti-double-stranded deoxy-
ribonucleic acid (DNA), anti-neutrophilic cytoplasmic
antibodies (ANCAs), C3, and C4 were normal. The results
of angiotensin converting enzyme, thyroid function tests,
Mantoux test, pulmonary function test, and abdominopel-
vic sonography were also normal. Serum and urine calcium
levels as well as X-rays of the bones of both her hands were
normal too. A computed tomography scan of her chest
revealed unilateral hilar adenopathy of her left lung. A
bronchoscopy was performed but was normal. Breast
sonography showed a 5×2cm abscess with inflammation
in its peripheral fat. Following the drainage of her breast
abscess, the specimen was sent for histopathologic
examination. In sections taken from the specimen, mul-
tiple granulomas composed of epithelioid histiocytes
and mononuclear infiltration with multinucleated giant
cells were observed, which generally suggested granu-
lomatous mastitis (Figures 1a and 1b). The results of
bacterial and fungal and mycobacterial cultures from
the abscess were negative. An acid-fast bacillus (AFB)
stain was negative as well. Based on the findings of uni-
lateral hilar adenopathy of her left lung and the presence
of erythema nodosum and granuloma in the biopsy, she
was diagnosed with sarcoidosis. A comprehensive review
of the literature revealed that both IFN-β and IFN-α may
induce sarcoidosis [4]. Thus, IFN-β-1b was discontinued
in the patient and glatiramer acetate was begun. She was
also treated with indomethacin and prednisolone, and she
improved in 4 weeks.
Discussion
Granulomatous mastitis has several etiologies. In general,
the etiology of this disorder can be divided into two major
groups including infectious and non-infectious causes. In-
fectious causes are the main cause of granuloma formation
in the human body [5] and granulomatosis can be caused
by mycobacterial, fungal and bacterial infections. Non-
infectious causes of granulomatosis mastitis are sarcoid-
osis, Wegener granulomatosis, and the reaction of a breast
to a foreign body [6]. Erythema nodosum is usually idio-
pathic. However, there are other possibilities which may
result in this non-specific cutaneous manifestation includ-
ing beta-hemolytic streptococcal infections, mycobacter-
ial infections, sarcoidosis, inflammatory bowel disease
(Crohn's disease and ulcerative colitis) and carcinoma
(mainly lymphoma or leukemia) [7].As mentioned above, the specimen cultures of bacter-
ial, fungal and mycobacterial infections were negative;
the results of the AFB stain and Mantoux test were
negative as well. In addition, the solid response to treat-
ment with prednisolone points towards a non-infectious
etiology. There was no evidence of any form of malig-
nancy in the pathological examination. Since ANCA was
normal, Wegener granulomatosis disease was excluded.
The patient did not have any gastrointestinal complaints
and inflammatory bowel disease is not a usual cause of
granulomatous mastitis.
The cutaneous manifestation of sarcoidosis is divided
into two different types: specific and non-specific [8]. As
granulomas are seen on biopsy, the sarcoid skin manifest-
ation will be entitled specific cutaneous sarcoid lesions [8].
In our case, granulomas were detected on breast biopsy.
So, the breast abscess of our patient is a specific kind of
sarcoid lesion. However, erythema nodosum is recognized
as the most common non-specific skin manifestation of
sarcoidosis [8]. Hence, it can be said that our case had
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To the best of our knowledge, only seven patients with
sarcoidosis following IFN-β therapy have been reported in
the literature. The initial report by Abdi et al. in 1987 re-
ported the case of a 57-year-old woman with renal cell
carcinoma who developed pulmonary sarcoidosis follow-
ing treatment with IFN-β and vinblastine [9]. Subsequent
reports include a case report by Bobbio-Pallavicini et al. in
1995 which discusses a woman diagnosed with multiple
myeloma who developed sarcoidosis involving different
organs, including liver, bone, and lungs following treat-
ment with IFN-β [10]. Mehta et al., in 1998, reported the
case of a 57-year-old man with MS who developed cutane-
ous sarcoidosis after being treated with IFN-β for 2 years
and 2 months [11]. More recently, in 2005, O'Reilly et al.
reported the case of another patient with pulmonary sar-
coidosis following weekly treatment with IFN-β [12]. Since
that time, three other patients have been reported, all pub-
lished in 2012. Of these three patients, one was a 39-year-
old woman with skin and pulmonary involvement after 3
years of IFN-β treatment, the second one was a 35-year-
old man who developed pulmonary sarcoidosis after 6
years of IFN-β treatment, and the third one was a 30-year-
old woman with a 5-month history of IFN-β treatment
who also had only pulmonary sarcoidosis [13-15]. The
present patient was a 33-year-old Caucasian woman with
MS who was treated with IFN-β for 2.5 years and devel-
oped both pulmonary and cutaneous sarcoidosis. From a
clinical standpoint, in all seven reported patients, IFN-β
was discontinued after the discovery of the adverse devel-
opments. The first patient was not treated [9]. However,
the second patient was treated with corticosteroids, and
the third patient recovered following treatment with a
combination of hydroxychloroquine, psoralen, and ultra-
violet A [10,11]. One patient improved without any
treatment and one was treated with prednisone, hydro-
xychloroquine, and methotrexate [8,9]. The final two re-
ported patients were treated with prednisolone and
hydroxychloroquine due to the continuity of the signs
and complaints, and prednisolone, respectively. In the
last patient, prednisolone resulted in complete reso-
lution [12,13]. Treatment of our patient with a combin-
ation of indomethacin and prednisolone caused a
significant decrease in the signs and symptoms. A total
of eight patients, including the current presented pa-
tient, have been reported to have sarcoidosis following
treatment with IFN-β, six of which were patients with
MS. The average duration of treatment with IFN-β was
28.1 months. In a considerable presentation, the rate of pul-
monary and skin involvement in these eight patients was
87.5% and 37.5%, respectively. While IFN-β-induced sar-
coidosis may appear to be a separate entity, further research
should be conducted to determine factors involved in the
occurrence of sarcoidosis following IFN-β treatment. Thedevelopment of sarcoidosis following treatment with IFN-β
seems evident; however, the event may be attributed to its
immunomodulatory properties or its effect on the activa-
tion of proinflammatory mediators, which can result in the
formation of granuloma [13]. The diagnosis of IFN-induced
sarcoidosis (IIS) in a patient with MS may be questionable
since it is difficult to establish a clear-cut causal relation-
ship. It is well known that sarcoidosis is a great imitator of
MS [16]. Therefore, views that the patients presented in this
report had from the beginning only sarcoidosis and not MS
should be taken into consideration. However, it should be
stressed that the available data on the ratio of involved or-
gans in the patients with IIS are different from natural sar-
coidosis [4], so it is most probable that IFN-β, similar to
IFN-α, can cause sarcoidosis in patients with MS due to its
immunomodulatory properties. Further, it should be noted
that the immunopathology of MS may actually contribute
to the induction of sarcoidosis in patients undergoing
IFN-β treatment. In general, this phenomenon is a form
“biologics-induced autoimmune disease”, which has been
recently described by Perez-Alvarez et al. and includes di-
verse autoimmune diseases caused by different biological
drugs [17].
Conclusions
Sarcoidosis is one of the differential diagnoses of MS.
The present case demonstrates that treatment with
IFN-β-1b can result in the development of sarcoidosis
in patients with MS. Therefore, in patients with respira-
tory or cutaneous symptoms, IFN-β-induced sarcoidosis
should be considered among differential diagnoses.
Cases of IFN-β-induced sarcoidosis are therapeutically
responsive to the discontinuation of the IFN-β and
treatment with corticosteroids.
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